Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Short term Debt (2020 - 2023)

GeneDx Holdings has reported Short term Debt over the past 4 years, most recently at $4.3 million for Q1 2023.

  • Quarterly Short term Debt rose 33.3% to $4.3 million in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $4.3 million through Mar 2023, up 33.3% year-over-year, with the annual reading at $3.6 million for FY2022, 36.98% up from the prior year.
  • Short term Debt was $4.3 million for Q1 2023 at GeneDx Holdings, up from $3.6 million in the prior quarter.
  • Over five years, Short term Debt peaked at $4.3 million in Q1 2023 and troughed at $797000.0 in Q1 2021.
  • The 4-year median for Short term Debt is $2.1 million (2022), against an average of $2.3 million.
  • The largest YoY upside for Short term Debt was 306.15% in 2022 against a maximum downside of 28.28% in 2022.
  • A 4-year view of Short term Debt shows it stood at $1.4 million in 2020, then surged by 84.07% to $2.6 million in 2021, then surged by 36.98% to $3.6 million in 2022, then increased by 20.09% to $4.3 million in 2023.
  • Per Business Quant, the three most recent readings for WGS's Short term Debt are $4.3 million (Q1 2023), $3.6 million (Q4 2022), and $1.8 million (Q3 2022).